Kiora PharmaceuticalsKPRX -0.77%33 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Kiora Pharmaceuticals ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kiora Pharmaceuticals EBITDA Margin % Related Terms
Kiora Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kiora Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPRX vs BRTX, INTS, ERNA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Kiora Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiora Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (KPRX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kiora Pharmaceuticals and its competitors. According to the industry distribution chart, Kiora Pharmaceuticals ranks #999999 out of 945 companies in the Biotechnology industry.
Is Kiora Pharmaceuticals' EBITDA Margin % too high?
Kiora Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Kiora Pharmaceuticals ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' EBITDA Margin % compare to BRTX and INTS?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #999999 out of 945 companies for EBITDA Margin %. This places Kiora Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Kiora Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
33GF Score
Get the complete analysis for KPRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPRX has been successfully added to your 
